

Medicyte GmbH Benefits From Multi-Million Euro EU Grant VascuBone.

Medicyte has been elected partner in the VascuBone project, in which 15 European partners from industry and academic institutions work on practical, yet individual solutions in bone regenerative medicine. The VascuBone project is supported by a 12 million Euro FP7 grant from the European Union starting in 2010 to 2015.

Heidelberg / Germany, March 30, 2010 – Medicyte GmbH (Medicyte) is a life science company specialised in the controlled, scalable generation and standardisation of human primary cell products. Medicyte's proprietary technologies upcyte® and vericyte® allow controlled proliferation of primary cells in vitro, without loss of phenotypic or cell differentiation properties. With these unique technologies, the company is ideally positioned to capitalize on the increasing demand for well-characterized high-quality primary cells for research and clinical applications. With its virtually unlimited supply of maximum-quality primary cells, Medicyte targets the current market for cells and cell systems as well as the emerging multi-billion Euro market for regenerative medicine.

Initiator and organizer of VascuBone is Prof. Dr. Heike Walles, recently appointed head of the Department for Regenerative Medicine at University of Würzburg. The goal of VascuBone (www.vascubone.eu) is to develop a 'tool box' for bone regeneration, which fulfils basic requirements and is freely combinable with what is needed in the respective patient's situation. Among others, the tool box will include a variation of biocompatible biomaterials and cell types. With the company's unique expertise and proprietary technologies, Medicyte's contribution will be to support in developing and supplying cells and cell factors for the VascuBone toolbox. The 15 project partners include Fraunhofer Institute, Johnson & Johnson Medical and Royal Institute of Technology, Sweden.

Dr. Joris Braspenning, Managing Director of Medicyte GmbH:

"Being elected as partner in this fantastic project is certainly an honour. Furthermore, it is a signal of high interest from industry and academic institutions in our technologies upcyte® and vericyte® and related cell products."

Contact: Medicyte GmbH
Stefan Holder
Im Neuenheimer Feld 581
69120 Heidelberg
Tel.: +49-6221-72925-30
E-Mail: assistant@medicyte.com
www.medicyte.com